Our COVID Vaccine Statement and other related resources for patients and our researchers and research staff are available on the COVID-19 Updates webpage.
Ramez Eskander MD
Temporarily Closed to Accrual
To assess the clinical activity (overall response rate) of tazemetostat in patients with recurrent or persistent endometrioid or clear cell ovarian carcinoma, and patients with recurrent or persistent endometrioid endometrial adenocarcinoma.
Women with pathologically proven diagnosis of recurrent or persistent ovarian endometrioid or clear cell carcinoma, OR recurrent or persistent endometrioid endometrial adenocarcinoma. Patients with recurrent endometrial cancer must have MMR immunohistochemistry completed. If they are found to be mismatch repair deficient, they should be offered treatment with immune checkpoint inhibition before consideration for treatment on this trial.
Primary ovarian tumors must be at least 50% endometrioid or clear cell morphology.
All patients must have measurable disease, and have had at least 1, but no more than 3, prior cytotoxic regimens for management of primary disease.
We are a leading protocol organizations within the National Clinical Trials Network and we seek to improve the lives of cancer patients by conducting practice-changing, multi-institutional clinical and translational research. Learn More
NRG Oncology Foundation, Inc, is a nonprofit, tax-exempt foundation. Donations to NRG Oncology help us conduct this important mission, and are tax-deductible to the extent permitted by law.